B–NHL Cases in a Tertiary Pediatric Hematology—Oncology Department: A 20-Year Retrospective Cohort Study
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Kaatsch, P. Epidemiology of Childhood Cancer. Cancer Treat. Rev. 2010, 36, 277–285. [Google Scholar] [CrossRef] [PubMed]
- Morton, L.M.; Wang, S.S.; Devesa, S.S.; Hartge, P.; Weisenburger, D.D.; Linet, M.S. Lymphoma Incidence Patterns by WHO Subtype in the United States, 1992–2001. Blood 2006, 107, 265–276. [Google Scholar] [CrossRef] [PubMed]
- Rosolen, A.; Perkins, S.L.; Pinkerton, C.R.; Guillerman, R.P.; Sandlund, J.T.; Patte, C.; Reiter, A.; Cairo, M.S. Revised International Pediatric Non-Hodgkin Lymphoma Staging System. J. Clin. Oncol. 2015, 33, 2112–2118. [Google Scholar] [CrossRef] [PubMed]
- Pfister, S.M.; Reyes-Múgica, M.; Chan, J.K.C.; Hasle, H.; Lazar, A.J.; Rossi, S.; Ferrari, A.; Jarzembowski, J.A.; Pritchard-Jones, K.; Hill, D.A.; et al. A Summary of the Inaugural WHO Classification of Pediatric Tumors: Transitioning from the Optical into the Molecular Era. Cancer Discov. 2022, 12, 331–355. [Google Scholar] [CrossRef] [PubMed]
- Alaggio, R.; Amador, C.; Anagnostopoulos, I.; Attygalle, A.D.; Araujo, I.B.d.O.; Berti, E.; Bhagat, G.; Borges, A.M.; Boyer, D.; Calaminici, M.; et al. The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022, 36, 1720–1748. [Google Scholar] [CrossRef]
- Egan, G.; Goldman, S.; Alexander, S. Mature B-NHL in Children, Adolescents and Young Adults: Current Therapeutic Approach and Emerging Treatment Strategies. Br. J. Haematol. 2019, 185, 1071–1085. [Google Scholar] [CrossRef] [PubMed]
- Kyriakidis, I.; Mantadakis, E.; Stiakaki, E.; Groll, A.H.; Tragiannidis, A. Infectious Complications of Targeted Therapies in Children with Leukemias and Lymphomas. Cancers 2022, 14, 5022. [Google Scholar] [CrossRef]
- Xavier, A.C.; Suzuki, R.; Attarbaschi, A. Diagnosis and Management of Rare Paediatric Non-Hodgkin Lymphoma. Best Pract. Res. Clin. Haematol. 2023, 36, 101440. [Google Scholar] [CrossRef]
- Crump, C.; Sundquist, K.; Sieh, W.; Winkleby, M.A.; Sundquist, J. Perinatal and Family Risk Factors for Non-Hodgkin Lymphoma in Early Life: A Swedish National Cohort Study. J. Natl. Cancer Inst. 2012, 104, 923–930. [Google Scholar] [CrossRef]
- Georgakis, M.K.; Karalexi, M.A.; Agius, D.; Antunes, L.; Bastos, J.; Coza, D.; Demetriou, A.; Dimitrova, N.; Eser, S.; Florea, M.; et al. Incidence and Time Trends of Childhood Lymphomas: Findings from 14 Southern and Eastern European Cancer Registries and the Surveillance, Epidemiology and End Results, USA. Cancer Causes Control 2016, 27, 1381–1394. [Google Scholar] [CrossRef]
- SEER*Explorer Application. Available online: https://seer.cancer.gov/statistics-network/explorer/application.html?site=86&data_type=1&graph_type=2&compareBy=sex&chk_sex_1=1&chk_sex_3=3&chk_sex_2=2&rate_type=2&race=1&age_range=15&stage=101&advopt_precision=1&advopt_show_ci=on&hdn_view=1&advopt_show_apc=on&advopt_display=1#resultsRegion1 (accessed on 9 August 2023).
- Chun, G.Y.C.; Sample, J.; Hubbard, A.K.; Spector, L.G.; Williams, L.A. Trends in Pediatric Lymphoma Incidence by Global Region, Age and Sex from 1988-2012. Cancer Epidemiol. 2021, 73, 101965. [Google Scholar] [CrossRef] [PubMed]
- Reedijk, A.M.J.; Beishuizen, A.; Coebergh, J.W.W.; Hoeben, B.A.W.; Kremer, L.C.M.; Hebeda, K.M.; Pieters, R.; Loeffen, J.L.C.; Karim-Kos, H.E. Progress against Non-Hodgkin’s Lymphoma in Children and Young Adolescents in the Netherlands since 1990: Stable Incidence, Improved Survival and Lower Mortality. Eur. J. Cancer 2022, 163, 140–151. [Google Scholar] [CrossRef] [PubMed]
- Liu, B.; Abraham, N.; Chitsike, I.; Sylvie, C.G.L.; Kambugu, J.; Stévy, N.M.A.; Pondy, A.H.O.; Renner, L.; Parkin, D.M. Enhancing Information on Stage at Diagnosis for Childhood Cancer in Africa. Pediatr. Blood Cancer 2023, 70, e30555. [Google Scholar] [CrossRef] [PubMed]
- Gaytan-Morales, F.; Alejo-Gonzalez, F.; Reyes-Lopez, A.; Palomo, M.; Rodriguez-Romo, L.; Villareal-Martínez, L.; Sandoval-González, A.; Lopez-Facundo, A.; Tejocote-Romero, I.; Cárdenas-Cardos, R.; et al. Pediatric Mature B-Cell NHL, Early Referral and Supportive Care Problems in a Developing Country. Hematology 2019, 24, 79–83. [Google Scholar] [CrossRef] [PubMed]
- Jin, S.L.; Hahn, S.M.; Kim, H.S.; Shin, Y.J.; Kim, S.H.; Lee, Y.S.; Lyu, C.J.; Han, J.W. Symptom Interval and Patient Delay Affect Survival Outcomes in Adolescent Cancer Patients. Yonsei Med. J. 2016, 57, 572–579. [Google Scholar] [CrossRef] [PubMed]
- Costa, A.R.S.; Costa, J.T.; Breviglieri, C.N.M.; Melgares, L.M.P.; Godinho, P.R.; Metzger, M.L. Children and Adolescents with Non-Hodgkin Lymphoma in Brazil: A National Survey Identifies the Challenges Encountered and Documents the Diversity of Care. Hematol. Transfus. Cell Ther. 2023, 45 (Suppl. S2), S36–S42. [Google Scholar] [CrossRef] [PubMed]
- Petridou, E.T.; Dikalioti, S.K.; Skalkidou, A.; Andrie, E.; Dessypris, N.; Trichopoulos, D.; The Childhood Hematology-Oncology Group. Sun Exposure, Birth Weight, and Childhood Lymphomas: A Case Control Study in Greece. Cancer Causes Control 2007, 18, 1031–1037. [Google Scholar] [CrossRef] [PubMed]
- Papadopoulou, C.; Antonopoulos, C.N.; Sergentanis, T.N.; Panagopoulou, P.; Belechri, M.; Petridou, E.T. Is Birth Weight Associated with Childhood Lymphoma? A Meta-Analysis. Int. J. Cancer 2012, 130, 179–189. [Google Scholar] [CrossRef] [PubMed]
- Rahiman, E.A.; Bakhshi, S.; Pushpam, D.; Ramamoorthy, J.; Das, A.; Ghara, N.; Kalra, M.; Kapoor, G.; Meena, J.P.; Siddaigarhi, S.; et al. Outcome and Prognostic Factors in Childhood B Non-Hodgkin Lymphoma from India: Report by the Indian Pediatric Oncology Group (InPOG-NHL-16-01 Study). Pediatr. Hematol. Oncol. 2022, 39, 391–405. [Google Scholar] [CrossRef]
- El-Mallawany, N.K.; Alexander, S.; Fluchel, M.; Hayashi, R.J.; Lowe, E.J.; Giulino-Roth, L.; Wistinghausen, B.; Hermiston, M.; Allen, C.E.; The COG NHL Committee. Children’s Oncology Group’s 2023 Blueprint for Research: Non-Hodgkin Lymphoma. Pediatr. Blood Cancer 2023, 70 (Suppl. S6), e30565. [Google Scholar] [CrossRef]
- Wang, X.-L.; Wang, X.-L.; He, S.; Zhai, H.-L. Association of Β2-Microglobulin with the Prognosis of Non-Hodgkin’s Lymphoma: A Meta Analysis. Int. J. Clin. Exp. Med. 2015, 8, 3992–3999. [Google Scholar]
- Ramadan, S.M.; Ceparano, G.; Cignetti, A.; Sammassimo, S.; Bagnardi, V.; Pagan, E.; Gottardi, D.; Fiori, S.; Passerini, R.; Radice, T.; et al. Prognostic Impact of the Baseline Immunologic Profile in Patients with Aggressive B Non-Hodgkin Lymphomas. Blood 2019, 134, 1522. [Google Scholar] [CrossRef]
- Lin, Y.; Gustafson, M.P.; Bulur, P.A.; Gastineau, D.A.; Witzig, T.E.; Dietz, A.B. Immunosuppressive CD14+HLA-DRlow/− Monocytes in B-Cell Non-Hodgkin Lymphoma. Blood 2011, 117, 872–881. [Google Scholar] [CrossRef] [PubMed]
- Wu, C.; Wu, X.; Liu, X.; Yang, P.; Xu, J.; Chai, Y.; Guo, Q.; Wang, Z.; Zhang, L. Prognostic Significance of Monocytes and Monocytic Myeloid-Derived Suppressor Cells in Diffuse Large B-Cell Lymphoma Treated with R-CHOP. Cell Physiol. Biochem. 2016, 39, 521–530. [Google Scholar] [CrossRef] [PubMed]
- Yu, R.; Cheng, L.; Yang, S.; Liu, Y.; Zhu, Z. iTRAQ-Based Proteomic Analysis Reveals Potential Serum Biomarkers for Pediatric Non-Hodgkin’s Lymphoma. Front. Oncol. 2022, 12, 848286. [Google Scholar] [CrossRef] [PubMed]
- Valkovic, T.; Gasic, V.; Nacinovic-Duletic, A. Multiple Myeloma Index for Risk of Infection. J. Cancer 2018, 9, 2211–2214. [Google Scholar] [CrossRef] [PubMed]
- Planinc-Peraica, A.; Kolonić, S.O.; Radić-Kristo, D.; Dominis, M.; Jaksić, B. Serum Immunoglobulins in Non-Hodgkin’s Lymphoma Patients. Coll. Antropol. 2010, 34, 407–411. [Google Scholar] [PubMed]
- Haddouche, M.; Meziane, W.; Hadjidj, Z.; Mesli, N.; Aribi, M. Clinical Association of Baseline Levels of Conjugated Dienes in Low-Density Lipoprotein and Nitric Oxide with Aggressive B-Cell Non-Hodgkin Lymphoma and Their Relationship with Immunoglobulins and Th1-to-Th2 Ratio. J. Blood Med. 2016, 7, 111–119. [Google Scholar] [CrossRef] [PubMed]
- Roy Moulik, N.; Singh Arora, R. Immunisation in Children with Cancer Treated with Standard Dose Chemotherapy- Review of Evidence. Pediatr. Hematol. Oncol. J. 2020, 5, 89–95. [Google Scholar] [CrossRef]
- Kyriakidis, I.; Vasileiou, E.; Rossig, C.; Roilides, E.; Groll, A.H.; Tragiannidis, A. Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies. J. Fungi 2021, 7, 186. [Google Scholar] [CrossRef]
- Samochatova, E.V.; Maschan, A.A.; Shelikhova, L.N.; Myakova, N.V.; Belogurova, M.B.; Khlebnikova, O.P.; Shamardina, A.V.; Ryskal, O.V.; Roumiantseva, J.V.; Konovalov, D.M.; et al. Therapy of Advanced-Stage Mature B-Cell Lymphoma and Leukemia in Children and Adolescents with Rituximab and Reduced Intensity Induction Chemotherapy (B-NHL 2004M Protocol): The Results of a Multicenter Study. J. Pediatr. Hematol. Oncol. 2014, 36, 395–401. [Google Scholar] [CrossRef]
- Hlavackova, E.; Krenova, Z.; Kerekes, A.; Slanina, P.; Vlkova, M. B Cell Subsets Reconstitution and Immunoglobulin Levels in Children and Adolescents with B Non-Hodgkin Lymphoma after Treatment with Single Anti CD20 Agent Dose Included in Chemotherapeutic Protocols: Single Center Experience and Review of the Literature. Biomed. Pap. [CrossRef]
- Alexander, S.; Aupérin, A.; Bomken, S.; Csóka, M.; Kazanowska, B.; Chiang, A.K.; Andres, M.; Uyttebroeck, A.; Burke, G.A.A.; Zsiros, J.; et al. Effect of Rituximab on Immune Status in Children with Mature B-Cell Non-Hodgkin Lymphoma: A Prespecified Secondary Analysis of the Inter-B-NHL Ritux 2010 Trial. Lancet Haematol. 2023, 10, e445–e457. [Google Scholar] [CrossRef] [PubMed]
- Moser, O.; Zimmermann, M.; Meyer, U.; Klapper, W.; Oschlies, I.; Schrappe, M.; Attarbaschi, A.; Mann, G.; Niggli, F.; Spix, C.; et al. Second Malignancies after Treatment of Childhood Non-Hodgkin Lymphoma—A Report of the Berlin-Frankfurt-Muenster Study Group. Haematologica 2020, 106, 1390–1400. [Google Scholar] [CrossRef]
- Ehrhardt, M.J.; Sandlund, J.T.; Zhang, N.; Liu, W.; Ness, K.K.; Bhakta, N.; Chemaitilly, W.; Krull, K.R.; Brinkman, T.M.; Crom, D.B.; et al. Late Outcomes of Adult Survivors of Childhood Non-Hodgkin Lymphoma: A Report from the St. Jude Lifetime Cohort Study. Pediatr. Blood Cancer 2017, 64, e26338. [Google Scholar] [CrossRef]
- Ehrhardt, M.J.; Dixon, S.B.; Belsky, J.; Hochberg, J. Late Effects and Frontline Treatment Selection for Children with Non-Hodgkin Lymphoma. Best Pract. Res. Clin. Haematol. 2023, 36, 101443. [Google Scholar] [CrossRef]
- Moosmann, J.; Krusemark, A.; Dittrich, S.; Ammer, T.; Rauh, M.; Woelfle, J.; Metzler, M.; Zierk, J. Age-and sex-specific pediatric reference intervals for neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, and platelet-to-lymphocyte ratio. Int. J. Lab. Hematol. 2022, 44, 296–301. [Google Scholar] [CrossRef] [PubMed]
n = 17 | Sex (M:F) | Median Age at Diagnosis (Range) | |
---|---|---|---|
B-NHL classification | |||
BL | 10 (58.8%) | 10:0 | 7.7 (4.3–10.4) |
PMBCL | 2 (11.8%) | 1:1 | 17.6 (12.8–22.3) |
DLBCL | 2 (11.8%) | 1:1 | 12.5 (9.2–15.8) |
BLL | 2 (11.8%) | 1:1 | 4.9 (4.7–5) |
FL | 1 (5.9%) | 0:1 | 14.1 |
Murphy staging | |||
Stage I | 6% | ||
Stage II | 12% | ||
Stage III | 53% | ||
Stage IV | 29% | ||
FAB/LMB risk stratification | |||
A | - | ||
B | 87% | ||
C | 13% | ||
BFM risk stratification | |||
R1 | - | ||
R2 | 53% | ||
R3 | 20% | ||
R4 | 27% |
Work-Up | Median | Range | % of Cohort with Abnormal Values for Age |
---|---|---|---|
WBC (/μL) | 8500 | 3800 to 62,500 | 12% |
Lymphocytes (/μL) | 2204 | 531 to 13,750 | 20% |
Lymphocyte proportion † (%) | 27.5 ± 13.3 | 20.2 to 34.9 | 12% |
Relative neutrophil count † (%) | 60.3 ± 15.2 | 51.8 to 68.7 | 18% |
Relative mononuclear cell population † (%) | 9.5 ± 4 | 7.3 to 11.7 | 41% |
Percentage of eosinophils † (%) | 2.3 ± 2 | 1.2 to 3.7 | None |
Hemoglobin † (g/dL) | 11.6 ± 1.4 | 10.9 to 12.4 | 6% |
Platelet count † (/μL) | 330,060 ± 117,736 | 265,400 to 395,800 | 6% |
Platelet-to-lymphocyte ratio | 152.6 | 2.8 to 580 | 60% |
Lymphocyte-to-monocyte ratio | 3.5 ± 2.5 | 2.1 to 4.9 | 53% |
LDH (U/L) | 397 | 194 to 14,640 | 73% |
ESR (mm/1 h) | 26 | 10 to 110 | 93% |
CRP (mg/dL) | 0.67 | 0.03 to 5.5 | 54% |
AST (U/L) | 30 | 18 to 281 | 40% |
ALT (U/L) | 18 | 9 to 67 | 20% |
GGT (U/L) | 14 | 8 to 110 | 33% |
Albumin † (g/dL) | 3.9 ± 0.5 | 3.6 to 4.2 | 33% |
Creatinine (mg/dL) | 0.56 | 0.4 to 1.2 | 13% |
C3 (mg/dL) | 128.5 | 119 to 184 | 17% |
Cystatin-C (mg/L) | 0.62 | 0.54 to 1.04 | 0 |
Ig | Levels at Diagnosis | Levels at the End of Chemotherapy | Days to Recover at Normal Levels |
---|---|---|---|
IgA (mg/dL) | 158.7 (±108.1) | 106.5 (±59.5) | 0 (0 to 3530) |
IgM (mg/dL) | 112.5 (±48.8) | 39.6 (15.6 to 195) | 359 (0 to 3530) |
IgG (mg/dL) | 1110.8 (±431.4) | 766.7 (±257.8) | 0 (0 to 1483) |
IgG1 (mg/dL) | 563.8 (±258) | 620.7 (±298.9) | NA |
IgG2 (mg/dL) | 168.8 (±81.1) | 270.3 (±129.4) | NA |
IgG3 (mg/dL) | 32.2 (±17.7) | 34.1 (±21.9) | NA |
IgG4 (mg/dL) | 11.4 (±9.3) | 19.1 (±14) | NA |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kyriakidis, I.; Pelagiadis, I.; Stratigaki, M.; Katzilakis, N.; Stiakaki, E. B–NHL Cases in a Tertiary Pediatric Hematology—Oncology Department: A 20-Year Retrospective Cohort Study. Life 2024, 14, 633. https://doi.org/10.3390/life14050633
Kyriakidis I, Pelagiadis I, Stratigaki M, Katzilakis N, Stiakaki E. B–NHL Cases in a Tertiary Pediatric Hematology—Oncology Department: A 20-Year Retrospective Cohort Study. Life. 2024; 14(5):633. https://doi.org/10.3390/life14050633
Chicago/Turabian StyleKyriakidis, Ioannis, Iordanis Pelagiadis, Maria Stratigaki, Nikolaos Katzilakis, and Eftichia Stiakaki. 2024. "B–NHL Cases in a Tertiary Pediatric Hematology—Oncology Department: A 20-Year Retrospective Cohort Study" Life 14, no. 5: 633. https://doi.org/10.3390/life14050633